191 related articles for article (PubMed ID: 37936223)
1. Proteomic biomarkers for survival in systemic sclerosis-associated pulmonary hypertension.
Mismetti V; Delavenne X; Montani D; Bezzeghoud S; Delezay O; Hodin S; Launay D; Marchand-Adam S; Nunes H; Ollier E; Reynaud-Gaubert M; Pastre J; Traclet J; Quetant S; Zeghmar S; Bertoletti L; Cottin V
Respir Res; 2023 Nov; 24(1):273. PubMed ID: 37936223
[TBL] [Abstract][Full Text] [Related]
2. Hemodynamic Response to Treatment and Outcomes in Pulmonary Hypertension Associated With Interstitial Lung Disease Versus Pulmonary Arterial Hypertension in Systemic Sclerosis: Data From a Study Identifying Prognostic Factors in Pulmonary Hypertension Associated With Interstitial Lung Disease.
Chauvelot L; Gamondes D; Berthiller J; Nieves A; Renard S; Catella-Chatron J; Ahmad K; Bertoletti L; Camara B; Gomez E; Launay D; Montani D; Mornex JF; Prévot G; Sanchez O; Schott AM; Subtil F; Traclet J; Turquier S; Zeghmar S; Habib G; Reynaud-Gaubert M; Humbert M; Cottin V
Arthritis Rheumatol; 2021 Feb; 73(2):295-304. PubMed ID: 32892515
[TBL] [Abstract][Full Text] [Related]
3. Impact of Systemic Sclerosis-Associated Interstitial Lung Disease With and Without Pulmonary Hypertension on Survival: A Large Cohort Study of the German Network for Systemic Sclerosis.
Moinzadeh P; Bonella F; Oberste M; Weliwitage J; Blank N; Riemekasten G; Müller-Ladner U; Henes J; Siegert E; Günther C; Kötter I; Pfeiffer C; Schmalzing M; Zeidler G; Korsten P; Susok L; Juche A; Worm M; Jandova I; Ehrchen J; Sunderkötter C; Keyßer G; Ramming A; Schmeiser T; Kreuter A; Lorenz HM; Hunzelmann N; Kreuter M
Chest; 2024 Jan; 165(1):132-145. PubMed ID: 37582424
[TBL] [Abstract][Full Text] [Related]
4. Clinical phenotypes, hemodynamic characteristics and prognosis of Chinese patients with systemic sclerosis-associated precapillary pulmonary hypertension: a retrospective study.
Yuan YP; Yuan P; Su YL; Jiang R; Zhang R; He J; Qiu HL; Luo CJ; Liu JM; Gong SG; Wang L; Zhao QH
Clin Rheumatol; 2022 Jun; 41(6):1675-1686. PubMed ID: 35099674
[TBL] [Abstract][Full Text] [Related]
5. Clinical characteristics and survival in systemic sclerosis-related pulmonary hypertension associated with interstitial lung disease.
Launay D; Humbert M; Berezne A; Cottin V; Allanore Y; Couderc LJ; Bletry O; Yaici A; Hatron PY; Mouthon L; Le Pavec J; Clerson P; Hachulla E
Chest; 2011 Oct; 140(4):1016-1024. PubMed ID: 21474572
[TBL] [Abstract][Full Text] [Related]
6. Integrative analysis of lung molecular signatures reveals key drivers of systemic sclerosis-associated interstitial lung disease.
Jung SM; Park KS; Kim KJ
Ann Rheum Dis; 2022 Jan; 81(1):108-116. PubMed ID: 34380701
[TBL] [Abstract][Full Text] [Related]
7. Prevalence, Treatment, and Outcomes of Coexistent Pulmonary Hypertension and Interstitial Lung Disease in Systemic Sclerosis.
Young A; Vummidi D; Visovatti S; Homer K; Wilhalme H; White ES; Flaherty K; McLaughlin V; Khanna D
Arthritis Rheumatol; 2019 Aug; 71(8):1339-1349. PubMed ID: 30762947
[TBL] [Abstract][Full Text] [Related]
8. Determinants of impairment in lung diffusing capacity in patients with systemic sclerosis.
Guarnieri G; Zanatta E; Mason P; Scarpa MC; Pigatto E; Maestrelli P; Cozzi F
Clin Exp Rheumatol; 2015; 33(4 Suppl 91):S80-6. PubMed ID: 25897784
[TBL] [Abstract][Full Text] [Related]
9. Survival in pulmonary hypertension associated with the scleroderma spectrum of diseases: impact of interstitial lung disease.
Mathai SC; Hummers LK; Champion HC; Wigley FM; Zaiman A; Hassoun PM; Girgis RE
Arthritis Rheum; 2009 Feb; 60(2):569-77. PubMed ID: 19180517
[TBL] [Abstract][Full Text] [Related]
10. Improved transplant-free survival in patients with systemic sclerosis-associated pulmonary hypertension and interstitial lung disease.
Volkmann ER; Saggar R; Khanna D; Torres B; Flora A; Yoder L; Clements PJ; Elashoff RM; Ross DJ; Agrawal H; Borazan N; Furst DE; Saggar R
Arthritis Rheumatol; 2014 Jul; 66(7):1900-8. PubMed ID: 24729406
[TBL] [Abstract][Full Text] [Related]
11. Pulmonary hypertension in systemic sclerosis: diagnosis by systematic screening and prognosis after three years follow-up.
Vilela VS; Dias MM; Salgado ÂA; da Silva BRA; Lopes AJ; Bessa EJC; Bruno LP; da Costa CH; Levy RA; Rufino R
BMC Pulm Med; 2021 Jul; 21(1):251. PubMed ID: 34325685
[TBL] [Abstract][Full Text] [Related]
12. Combined Pulmonary Fibrosis and Emphysema in Scleroderma-Related Lung Disease Has a Major Confounding Effect on Lung Physiology and Screening for Pulmonary Hypertension.
Antoniou KM; Margaritopoulos GA; Goh NS; Karagiannis K; Desai SR; Nicholson AG; Siafakas NM; Coghlan JG; Denton CP; Hansell DM; Wells AU
Arthritis Rheumatol; 2016 Apr; 68(4):1004-12. PubMed ID: 26636545
[TBL] [Abstract][Full Text] [Related]
13. Protein profiling in systemic sclerosis patients with different pulmonary complications using proteomic antibody microarray.
Huang J; Zhu H; Liu S; Li M; Li Y; Luo H; Zuo X
Arthritis Res Ther; 2024 Jan; 26(1):29. PubMed ID: 38233947
[TBL] [Abstract][Full Text] [Related]
14. Elevated serum Krebs von den Lungen-6 in systemic sclerosis: a marker of lung fibrosis and severity of the disease.
Benyamine A; Heim X; Resseguier N; Bertin D; Gomez C; Ebbo M; Harlé JR; Kaplanski G; Rossi P; Bardin N; Granel B
Rheumatol Int; 2018 May; 38(5):813-819. PubMed ID: 29455320
[TBL] [Abstract][Full Text] [Related]
15. Interstitial lung disease increases mortality in systemic sclerosis patients with pulmonary arterial hypertension without affecting hemodynamics and exercise capacity.
Michelfelder M; Becker M; Riedlinger A; Siegert E; Drömann D; Yu X; Petersen F; Riemekasten G
Clin Rheumatol; 2017 Feb; 36(2):381-390. PubMed ID: 28028682
[TBL] [Abstract][Full Text] [Related]
16. Limitations to the 6-minute walk test in interstitial lung disease and pulmonary hypertension in scleroderma.
Garin MC; Highland KB; Silver RM; Strange C
J Rheumatol; 2009 Feb; 36(2):330-6. PubMed ID: 19208563
[TBL] [Abstract][Full Text] [Related]
17. Systemic sclerosis-related pulmonary hypertension associated with interstitial lung disease: impact of pulmonary arterial hypertension therapies.
Le Pavec J; Girgis RE; Lechtzin N; Mathai SC; Launay D; Hummers LK; Zaiman A; Sitbon O; Simonneau G; Humbert M; Hassoun PM
Arthritis Rheum; 2011 Aug; 63(8):2456-64. PubMed ID: 21538327
[TBL] [Abstract][Full Text] [Related]
18. Mortality and hospitalization outcomes of interstitial lung disease and pulmonary hypertension in the Singapore systemic sclerosis cohort.
Noviani M; Saffari SE; Tan JL; Yip JWL; Teng GG; Law WG; Chan GYL; Santosa A; Lim AYN; Hong C; Ng SA; Tay ELW; Ruan W; Yap J; Low AHL
Semin Arthritis Rheum; 2020 Jun; 50(3):473-479. PubMed ID: 31810742
[TBL] [Abstract][Full Text] [Related]
19. Does Systemic Sclerosis-associated Interstitial Lung Disease Burn Out? Specific Phenotypes of Disease Progression.
Guler SA; Winstone TA; Murphy D; Hague C; Soon J; Sulaiman N; Li KH; Dunne J; Wilcox PG; Ryerson CJ
Ann Am Thorac Soc; 2018 Dec; 15(12):1427-1433. PubMed ID: 30188737
[TBL] [Abstract][Full Text] [Related]
20. Prevalence and characteristics of moderate to severe pulmonary hypertension in systemic sclerosis with and without interstitial lung disease.
Launay D; Mouthon L; Hachulla E; Pagnoux C; de Groote P; Remy-Jardin M; Matran R; Lambert M; Queyrel V; Morell-Dubois S; Guillevin L; Hatron PY
J Rheumatol; 2007 May; 34(5):1005-11. PubMed ID: 17444586
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
